摘要
抗精神病药物是治疗功能性精神病的主要药物,然而在使用这些药物的过程中可能诱导体重增加、糖代谢紊乱、血清瘦素水平升高及胰岛素抵抗。导致体重增加的假设,认为可能通过对H—5HT_(2A)或5—HT_(2C)受体以及组胺H1受体的拮抗引起的。对糖尿病及精神病进行有效控制。
出处
《国外医学(老年医学分册)》
2004年第3期135-138,共4页
Foreign Medical Sciences(Geriatrics)
参考文献9
-
1Koro CE, Fedder DO, L' Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case- control study. BMJ, 2002; 325:243~245
-
2Chue P, Welch R. Investigation of the metabolic effets of antipsychotics in patients with schizophrenia (poster). Presented at the 51st Annual Meeting of the Canadian Psychiatric Association, Quebec, 2001
-
3Koller EA, Doraiswamy PM. Olanzapine - associateddiabetes mellitus. Pharmacotherapy, 2002; 22:841-852
-
4Sernyak MJ, Douglas DL, Alarcon RD et al. Assciated diabetes mellitus with se of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 2002; 15:561-566
-
5UKPDS Study Group. Characteristics of newly presenting type 2 diabetes patients: male preponderance and obesity at different age. Diabet Med, 1998; 5:154-159
-
6Dwyer DS, Pinkofsky HB, Liu Y et al. Antipsychotic drugs affect glucose uptake and the express of gluoose transports in PCI12 cells. Prog Neuropsychopharmacol Biol psychiatry,1999; 23:69-80
-
7Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry, 2002; 57:12-15
-
8Lund BC, Perry PJ, Brooks J Ⅱ. Clozapine use in patients with schizophrenia and the risk of diabetes、 hyperlipidemia and hypertension: a claims - based approach. 2001; 58 (12):1172- 1176
-
9Fuller ⅢA, Shermoch KⅢ, SeicⅢ et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olznzapine. Pharmacotherepy, 2003; 23(8): 1037- 1043
同被引文献28
-
1刘俊彪,吴靖华.氯丙嗪、氯氮平、利培酮对首发精神分裂症患者糖代谢、血脂和体重的影响[J].中国神经精神疾病杂志,2004,30(4):293-295. 被引量:41
-
2刘素芳,魏平,王世贵,王东平,王云,马慧娟,贾福军.不同剂量氯氮平与精神分裂症患者血脂、血糖代谢的对照研究[J].中华精神科杂志,2005,38(2):82-85. 被引量:31
-
3Semyak MJ,Leslie DL. Alarcon BD. et al. Association of diabetes metlkus with use of atypical neuroleptics in thetreatment of schizophrenia[ J]. Am J Psychiatry ,2002,159:561-566.
-
4Wirshing DA, Spellberg B J, Erhart SM, et al. Novel antipsychotics and new onset diabetes[ J]. Bid Psychiatry,1998,4:778-783.
-
5Casey DE, Zorn SH, The pharmacology of weight gain with antipsyc-hotics[ J]. J Clin Psychiatry 2001,62 : 4-10.
-
6Lane HY, Chang YC, Chiu CC, et al. Association of risperidone treatment response with a polymorphism in the 5 -HTeA receptor gene[ J ]. Am J Psychiatry,2002,159 : 1593-1595.
-
7Kmus T, Haack M, Schuld A, et al. Body weisht and leptin plasma levels during treatment with antipsychotic drugs [ J ]. Am J Psychiatry,1999,156:31.
-
8Hoffstedt J, Eriksson P, Mottagui TS, et al. A polymorphism in the leptin promoter region (-2548 G/A ) influencesgene expression and adipo-se tissue secretion of leptin [ J ]. HormMetab Res,2002, 34 : 355-359.
-
9Deyer DS, Pinkofsky HB, Liu Yet al. Antipsychotic drugs affect gluccse uptake and the express of gluccess transports in PCI12 cells[J]. Prog Neuropsyc-hopharmacol Biol psychiatry, 1999,23; 69-80.
-
10Melksson K. uhing AI. Antipsychotic drugs can affect hormone balance, eight gain. lood lipid disturbances and diabetes are important [ J ]. Lakartidninger,2001,8 : 54 -62.
二级引证文献15
-
1卢勇.利培酮(可同)与喹硫平(舒思)治疗精神分裂症的比较[J].中国实用医药,2011,6(32):174-176. 被引量:1
-
2姚明荣,胡少华.奥氮平致糖脂代谢紊乱的病理机制[J].国际精神病学杂志,2012,39(2):122-125. 被引量:8
-
3夏旭兰,叶兴荣,陈海燕,董伟,周永富,黄嵘,冯旭薇,张晓斌.长期服用氯氮平的精神分裂症患者糖代谢随访研究[J].中国民康医学,2012,24(23):2835-2837. 被引量:1
-
4胡红霞,赵倩,白天山,崔素华,任玉红,王旭红,李小全.利培酮和氯氮平、喹硫平对精神分裂症患者脂代谢影响比较[J].中国卫生检验杂志,2012,22(12):2878-2879. 被引量:1
-
5施炜,丁顺娥.二甲双胍治疗抗精神病药所致高催乳素血症患者的初步观察[J].临床精神医学杂志,2013,23(6):408-409. 被引量:5
-
6张星亮,李小云,高玲玲,倪耀文.三种非典型抗精神病药对精神分裂症首发患者代谢影响的临床研究[J].中国药物与临床,2014,14(1):117-119. 被引量:14
-
7崔界峰,杨薇,谢雁鸣,孙勇,庄严,王永炎.基于真实世界的失眠患者合并疾病及用药情况分析[J].中国中药杂志,2014,39(18):3519-3526. 被引量:26
-
8张艳琦,于振东.氨磺必利与喹硫平对精神分裂症患者体质量指数及糖脂代谢的影响[J].中国民康医学,2015,27(9):41-42. 被引量:3
-
9刘毅,廖世棚,戢秋明,李驰.奥氮平和帕利哌酮对首发精神分裂症患者的糖代谢影响[J].中国健康心理学杂志,2015,23(7):964-966. 被引量:3
-
10马奇,李丽霞,连和谈.帕利哌酮和阿立哌唑对奥氮平所致体重增加的精神分裂症患者替代治疗研究[J].国际精神病学杂志,2018,45(1):59-61. 被引量:8
-
1葛红.误诊为精神疾病的中枢神经系统感染2例分析[J].吉林医学,2010,31(20):3380-3381. 被引量:1
-
2邵仲英,谭玲,封宇飞.H_1受体拮抗剂的不良反应及合理应用[J].药物不良反应杂志,2006,8(1):30-32. 被引量:13
-
3倪红,朱向香,郑卜真,王恩,马传花,周元林,蒋辉华,储照虎.奥氮平与喹硫平治疗病毒性脑炎精神障碍的对照研究[J].浙江医学,2015,37(9):784-785. 被引量:2
-
4栗强,侯广才,王千里,程卯生.药物发现新靶点——5-HT_(2C)受体[J].中国新药杂志,2003,12(5):326-329. 被引量:3
-
5申慧梅,王卫华,杨洁.富马酸卢帕他定片Ⅲ期临床试验的护理体会[J].中国药物与临床,2010,10(10):1203-1204.
-
6陈晨,张建宁,杨卫东,王邦茂,毓青.5-羟色胺及其受体与癫痫关系的研究进展[J].国际神经病学神经外科学杂志,2010,37(4):325-328. 被引量:7
-
7陈春琳.病毒性脑炎124例临床分析[J].昆明医学院学报,2011,32(6):155-156.
-
8梁月晴.第二代组胺H_1受体阻滞药的不良反应[J].中国药师,2000,3(4):235-237. 被引量:2
-
9冯贵宁.以精神障碍为首发症状的病毒性脑炎52例临床特点分析[J].广西医学,2007,29(10):1599-1600. 被引量:3
-
10宁尚节,宋志强,高启富.59例散发性脑炎临床分析[J].青海医药杂志,1994,24(1):20-21.